Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline of 2.8% as of October 30, 2025, with significant net outflows from major funds, indicating potential concerns among institutional investors [1][2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.9 million yuan, an increase of 5.89% [3]. - The company's gross margin stands at 39.34%, with a net profit margin of 17.43% [3]. Market Position - Meihao Medical's total market capitalization is 13.021 billion yuan, ranking 23rd in the medical device industry, while its net assets are 3.702 billion yuan, ranking 41st [3]. - The company has a price-to-earnings ratio (P/E) of 46.91, which is lower than the industry average of 60.08, ranking 53rd [3]. - The return on equity (ROE) is 5.79%, significantly higher than the industry average of 0.15%, ranking 43rd [3]. Fund Flow Analysis - On October 30, 2025, the net outflow of major funds was 8.9506 million yuan, accounting for 9.41% of the total transaction amount, while retail investors saw a net inflow of 8.6334 million yuan, representing 9.08% [1][2]. - Over the past five days, the stock has seen fluctuating fund flows, with significant net outflows from major funds on multiple days [2]. Analyst Ratings - In the last 90 days, 17 institutions have rated the stock, with 15 buy ratings and 2 hold ratings, indicating a generally positive outlook among analysts [4]. - The average target price set by institutions over the past 90 days is 25.2 yuan [4].
股票行情快报：美好医疗（301363）10月30日主力资金净卖出895.06万元